Thu Sep 26 15:00:00 UTC 2024: ## Public Employees Retirement Association of Colorado Cuts Holdings in Blueprint Medicines

**Denver, Colorado** – The Public Employees Retirement Association of Colorado (PERA) has reduced its stake in Blueprint Medicines Co. (NASDAQ:BPMC) by 9.3% in the second quarter, according to the company’s latest Form 13F filing with the Securities and Exchange Commission (SEC).

PERA now owns 6,512 shares of the biotechnology company’s stock, valued at $702,000, after selling 664 shares during the period.

This move comes amid a flurry of activity from other institutional investors in Blueprint Medicines. Triad Wealth Partners LLC acquired a new position in the company during the second quarter, worth $27,000. Covestor Ltd significantly increased its stake in Blueprint Medicines by 9,700% in the first quarter, now owning 294 shares valued at $28,000.

Headlands Technologies LLC also boosted its holdings in the company by 105.2% during the first quarter, now owning 667 shares valued at $63,000. Natixis purchased a new position in Blueprint Medicines during the first quarter, worth approximately $73,000. And CWM LLC raised its stake in the company by 114.6% during the second quarter, now owning 1,105 shares worth $119,000.

Despite the mixed investor activity, several brokerages remain optimistic about Blueprint Medicines. Oppenheimer recently lifted its price target on the stock from $114.00 to $125.00, giving it an “outperform” rating. Robert W. Baird also upped its target price from $112.00 to $127.00, assigning an “outperform” rating to the company.

Needham & Company LLC restated its “buy” rating and issued a $130.00 price objective on shares of Blueprint Medicines. Meanwhile, Morgan Stanley lifted its target price from $110.00 to $115.00 but gave the stock an “equal weight” rating.

Overall, analysts remain positive about Blueprint Medicines, with a consensus rating of “Moderate Buy” and a consensus price target of $120.00.

The company’s stock opened at $87.00 on Thursday. Blueprint Medicines develops precision therapies for genomically defined cancers and blood disorders.

Read More